Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, TexasOral presentation included data from MuSK-MG rat model depicting increases in muscle function and...
-
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, TexasOral presentation included data from MuSK-MG rat model depicting increases in muscle function and...
-
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing...
-
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing...
-
Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as...
-
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd orphan drug designation granted to the skeletal...
-
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd orphan drug designation granted to the skeletal...
-
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology Results from the ESTABLISH1 observational study confirms...
-
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
-
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...